Partex.AI and leadXpro announce collaboration to expand indications and support out-licensing of A2BR antagonist program

Eschborn, Germany and Villigen, Switzerland — 27/01/2026 —

Partex.AI (“Partex”), an AI-driven therapeutic asset incubator and accelerator, and leadXpro AG (“leadXpro”), a Switzerland-based pharmaceutical research and development company, today announced that they have entered into a collaboration agreement focused on expanding the therapeutic potential and supporting the future out-licensing of leadXpro’s adenosine A2B receptor (A2BR) antagonist program.

Under the agreement, Partex will apply its proprietary AI platform to identify and prioritize new therapeutic indications beyond LeadXpro’s current development focus and support the identification of potential licensing partners and downstream partnering activities. leadXpro will continue to lead research and preclinical development, contributing its expertise in medicinal chemistry and translational drug development. Dr. Frank Grams, Chief Commercial Officer of Partex, noted that the collaboration reflects Partex’s commitment to expanding the value of promising assets by combining data-driven insights with its global partnering network to support future licensing opportunities.

A2BR antagonists are a well-validated therapeutic class with applications across immunooncology, inflammation, and central nervous system disorders. By combining LeadXpro’s discovery know-how with Partex’s analytical and partnering capabilities, the collaboration aims to accelerate strategic decision-making, refine indication positioning, and efficiently advance partnering opportunities. Dr. Michael Hennig, Chief Executive Officer of leadXpro, added that Partex brings strong analytical capabilities and transaction experience that support leadXpro’s efforts to explore new indications and position the program for future partnering, while allowing the company to remain focused on advancing the science.

About Partex N.V.

Partex N.V. is a public company incorporated under the laws of the Netherlands and registered with the Netherlands Chamber of Commerce under KVK number 85275549. The Company’s principal place of business is at Frankfurter Strasse 27, 65760 Eschborn, Germany. Partex is engaged in AI-based drug discovery and has developed a proprietary technology platform that delivers diverse recommendations on alternative targets, indications, and development strategies to accelerate and de-risk pharmaceutical R&D.

About leadXpro AG

leadXpro AG is a private corporation (Aktiengesellschaft, CH-400.3.440.536-2) incorporated under the laws of Switzerland, with its principal location of business at Park Innovaare, Parkstrasse 1, CH-5234 Villigen, Switzerland. leadXpro is engaged in the enablement of structure- based drug discovery with a strong focus on translating innovative science into high-quality drug candidates.